Treats dry eye disease (DED). Sold as Miebo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Perfluorohexyloctane (sold as Miebo), first approved May 18, 2023, with 0 new uses approved and 0 published complete response letters.
| Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry EyeDry Eye · Beijing Tongren Hospital | Phase 4 | Not yet recruiting | Jul 1, 2026 |
| A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)Dry Eye Disease · Xiamen Ophthalmology Center Affiliated to Xiamen University | — | Not yet recruiting | Mar 9, 2026 |
| A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.Dry Eye · Bausch & Lomb Incorporated | Phase 4 | Active, not recruiting | Aug 22, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 18, 2023 | MieboNDA 216675 · New molecular entity | Bausch And Lomb Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
